[go: up one dir, main page]

MEP60808A - Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability - Google Patents

Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability

Info

Publication number
MEP60808A
MEP60808A MEP-608/08A MEP60808A MEP60808A ME P60808 A MEP60808 A ME P60808A ME P60808 A MEP60808 A ME P60808A ME P60808 A MEP60808 A ME P60808A
Authority
ME
Montenegro
Prior art keywords
zinc
insulin
contain
small quantity
improved stability
Prior art date
Application number
MEP-608/08A
Other languages
Bosnian (bs)
Inventor
Peter Boderke
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MEP60808A publication Critical patent/MEP60808A/en
Publication of ME00408B publication Critical patent/ME00408B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ovaj pronalazak se odnosi na neku farmaceutsku formulaciju koja sadrži neki polipeptid, koji je izabran iz grupe koja obuhvata insulin, neki metabolit insulina, neki analog insulina, neki derivate insulina ili njihove kombinacije; neki tenzid ili kombinacije više tenzida; po izboru neko sredstvo za konzerviranje ili kombinacije više sredstava za konzerviranje; i po izboru neko sredstvo za izotonizaciju, pufer ili druge pomoćne supstanca ili njihove kombinacije, pri čemu farmaceutska formulacija ne sadrži cink ili sadrži neznatne količine cinka. Pronalazak se odnosi isto tako na proizvodnju takvih insulinskih preparata.The present invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group comprising insulin, an insulin metabolite, an insulin analog, some insulin derivatives, or combinations thereof; some surfactant or multiple surfactant combinations; optionally a preservative or a combination of several preservatives; and optionally an isotonizing agent, buffer or other adjuvants or combinations thereof, wherein the pharmaceutical formulation contains no zinc or contains minor amounts of zinc. The invention also relates to the manufacture of such insulin preparations.

MEP-2008-608A 2001-03-23 2002-03-09 ZINC FREE AND ZINC ARM INSULIN PREPARATIONS WITH IMPROVED STABILITY ME00408B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10114178A DE10114178A1 (en) 2001-03-23 2001-03-23 Zinc-free and low-zinc insulin preparations with improved stability
PCT/EP2002/002625 WO2002076495A1 (en) 2001-03-23 2002-03-09 Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability
YU73503A RS51579B (en) 2001-03-23 2002-03-09 Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability

Publications (2)

Publication Number Publication Date
MEP60808A true MEP60808A (en) 2011-05-10
ME00408B ME00408B (en) 2011-10-10

Family

ID=7678654

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-608A ME00408B (en) 2001-03-23 2002-03-09 ZINC FREE AND ZINC ARM INSULIN PREPARATIONS WITH IMPROVED STABILITY

Country Status (32)

Country Link
US (5) US6960561B2 (en)
EP (2) EP1381385B1 (en)
JP (1) JP4231292B2 (en)
KR (2) KR100987311B1 (en)
CN (1) CN1273187C (en)
AR (2) AR033059A1 (en)
AT (1) ATE497777T1 (en)
AU (1) AU2002302409B2 (en)
BR (1) BRPI0208210B8 (en)
CA (1) CA2441260C (en)
CY (2) CY1111413T1 (en)
DE (2) DE10114178A1 (en)
DK (2) DK1381385T3 (en)
ES (2) ES2393180T3 (en)
HK (1) HK1061521A1 (en)
HR (1) HRP20030765B1 (en)
HU (1) HU228847B1 (en)
IL (2) IL158057A0 (en)
ME (1) ME00408B (en)
MX (1) MXPA03007942A (en)
MY (1) MY129417A (en)
NO (1) NO326780B1 (en)
NZ (1) NZ528335A (en)
PE (1) PE20020968A1 (en)
PL (1) PL205465B1 (en)
PT (2) PT1381385E (en)
RS (1) RS51579B (en)
RU (1) RU2311922C2 (en)
SI (1) SI1381385T1 (en)
TW (1) TWI301761B (en)
WO (1) WO2002076495A1 (en)
ZA (1) ZA200306637B (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2283705A1 (en) * 1997-03-20 1998-10-01 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
DE10114178A1 (en) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
US20050250676A1 (en) * 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
DE10227232A1 (en) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
DE10250297A1 (en) * 2002-10-29 2004-05-19 Aventis Pharma Deutschland Gmbh Insulin analog crystals and process for their preparation
WO2004096266A1 (en) * 2003-05-02 2004-11-11 Novo Nordisk A/S Improved physical stability of insulin formulations
BRPI0413276B8 (en) 2003-08-05 2021-05-25 Novo Nordisk As insulin derivative, zinc complex thereof, and pharmaceutical composition
CA2553392A1 (en) * 2004-01-16 2005-08-11 Biodel Inc Sublingual drug delivery device
ES2344303T3 (en) * 2004-02-13 2010-08-24 Nod Pharmaceuticals, Inc. PARTICLES THAT INCLUDE A NUCLEO OF CALCICO PHOSPHATE NANOPARTICLES, A BIOMOLECULA AND A BILIAR ACID, PRODUCTION METHODS AND THERAPEUTIC USE OF THE SAME.
ES2328048T3 (en) * 2004-03-12 2009-11-06 Biodel, Inc. INSULIN COMPOSITIONS WITH IMPROVED ABSORPTION.
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
CN101027318B (en) 2004-07-19 2016-05-25 比奥孔有限公司 Insulin-oligomer conjugates, preparation and uses thereof
JP2006087815A (en) * 2004-09-27 2006-04-06 Canon Inc Spraying method, and spraying apparatus based on the method
US20060194762A1 (en) * 2004-12-23 2006-08-31 Olaf Reer Composition comprising an epothilone and methods for producing a composition comprising an epothilone
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN101389650B (en) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 Compositions comprising an acylated insulin and zinc and method of making the said compositions
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
CA2649109A1 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
US20100120660A1 (en) * 2007-04-30 2010-05-13 Per Balschmidt Highly concentrated insulin solutions and compositions
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
CN101795680A (en) * 2007-11-16 2010-08-04 波苏蛋白试剂公司 excipients for protein stabilization
CN102026666B (en) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 Formulation of insulinotropic peptide conjugates
CN102007143B (en) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 There is the novel insulin derivates of super delayed aging feature
KR101239008B1 (en) * 2008-03-31 2013-03-04 한양대학교 산학협력단 Bilic acid derivatives and their applications
JP2010063762A (en) * 2008-09-12 2010-03-25 Yoshiharu Masui Antibacterial deodorant
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
MX2011004357A (en) 2008-10-30 2011-05-23 Novo Nordisk As Treating diabetes melitus using insulin injections with less than daily injection frequency.
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
RU2533217C3 (en) * 2009-06-26 2020-12-21 Ново Нордиск А/С PREPARATION CONTAINING INSULIN, NICOTINAMIDE AND AMINO ACID
SG177567A1 (en) * 2009-07-06 2012-02-28 Sanofi Aventis Deutschland Aqueous insulin preparations containing methionine
HUE038147T2 (en) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1-agonist, an insulin, and methionine
WO2011058082A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist and methionine
CN101912600B (en) * 2010-01-11 2014-01-29 杨国汉 Method for improving stability of insulin in solution
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP6049625B2 (en) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス Treatment of diabetes mellitus using insulin injections given at various injection intervals
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (en) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland PHARMACEUTICAL COMBINATION FOR USE IN GLUCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
EP2771026A4 (en) 2011-10-27 2015-08-05 Univ Case Western Reserve QUICKLY ULTRA-CONCENTRATED INSULIN ANALOG FORMULATIONS
CN107952065A (en) 2012-11-13 2018-04-24 阿道恰公司 Include the Insulin Aspart for being substituted anionic compound
TWI780236B (en) 2013-02-04 2022-10-11 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
HUE042381T2 (en) 2013-04-03 2019-06-28 Sanofi Sa Treatment of diabetes with long acting insulin preparations
JP2016519127A (en) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス New dosing regimen
AR098168A1 (en) * 2013-10-25 2016-05-04 Sanofi Sa STABLE FORMULATION OF GLULISINE INSULIN
CA2932875A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015104310A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
JP6641280B2 (en) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ Stabilized pharmaceutical formulations of insulin analogues and / or insulin derivatives
AR099569A1 (en) 2014-02-28 2016-08-03 Novo Nordisk As INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
HRP20230470T1 (en) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
AR102869A1 (en) 2014-12-16 2017-03-29 Lilly Co Eli QUICK ACTION INSULIN COMPOSITIONS
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
JP2018531900A (en) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス Novel insulin derivatives and their medical use
CN108368163A (en) 2015-08-25 2018-08-03 诺和诺德股份有限公司 Novel insulin derivates and its medical usage
US20190010206A1 (en) 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
JO3749B1 (en) 2015-08-27 2021-01-31 Lilly Co Eli Rapid-acting insulin compositions
CN105749292A (en) * 2016-02-29 2016-07-13 苏州市贝克生物科技有限公司 Composition for promoting insulin absorption and preparation method of composition
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
CN109803639B (en) 2016-09-29 2024-01-02 艾瑞克有限公司 New formulation
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
CR20190522A (en) 2017-06-01 2020-01-15 Lilly Co Eli Rapid-acting insulin compositions
EP3773474A1 (en) 2018-04-04 2021-02-17 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
WO2019193351A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
IL277731B2 (en) 2018-04-04 2024-03-01 Arecor Ltd A medical infusion pump system for administration of an insulin compound
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3083700B1 (en) * 2018-07-13 2021-03-12 Adocia THERMOSTABLE FORMULATION OF HUMAN INSULIN A21G
CA3120619A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
KR20220011697A (en) 2019-05-22 2022-01-28 바이오비에 아이앤씨. Terlipressin Formulation
CA3157995A1 (en) 2019-10-25 2021-04-29 Cercacor Laboratories, Inc. Indicator compounds, devices comprising indicator compounds, and methods of making and using the same
WO2021116292A1 (en) 2019-12-11 2021-06-17 Novo Nordisk A/S Novel insulin analogues and uses thereof
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758683A (en) 1971-04-30 1973-09-11 R Jackson Insulin product
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1527605A (en) 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
DE3064888D1 (en) * 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JPS55153712A (en) 1979-05-18 1980-11-29 Kao Corp Insulin pharmaceutical preparation and its production
DE3033127A1 (en) 1980-09-03 1982-04-08 Hoechst Ag, 6000 Frankfurt NEW INSULIN ANALOG
WO1983000288A1 (en) 1981-07-17 1983-02-03 Balschmidt, Per A stable aqueous, therapeutic insulin preparation and a process for preparing it
NL193099C (en) 1981-10-30 1998-11-03 Novo Industri As Stabilized insulin solution.
DE3316363A1 (en) 1983-05-05 1984-11-08 Deutsche Babcock Anlagen Ag, 4200 Oberhausen ROLLER GRID FOR WASTE COMBUSTION PLANTS
DE3326473A1 (en) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt PHARMACEUTICAL AGENT FOR TREATING THE DIABETES MELLITUS
DE3326472A1 (en) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt NEW INSULIN DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AND PHARMACEUTICAL AGENTS FOR TREATING THE DIABETES MELLITUS
DE3327709A1 (en) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt INSULIN DERIVATIVE CRYSTAL SUSPENSIONS, METHOD FOR THE PRODUCTION AND USE THEREOF
DE3327713A1 (en) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt WATER-SOLUBLE DISAZO COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS DYES
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
CA1244347A (en) * 1984-05-29 1988-11-08 Eddie H. Massey Stabilized insulin formulations
EP0166971B1 (en) 1984-06-09 1990-02-28 Hoechst Aktiengesellschaft Insulin preparations, process for their preparation and their use
KR860001166B1 (en) * 1984-06-15 1986-08-20 곽성일 A method of manufacturing eyelets for footwears
DE3440988A1 (en) 1984-11-09 1986-07-10 Hoechst Ag, 6230 Frankfurt METHOD FOR CLEAVING PEPTIDES AND PROTEINS ON THE METHIONYL BOND
DK347086D0 (en) 1986-07-21 1986-07-21 Novo Industri As NOVEL PEPTIDES
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK113585D0 (en) 1985-03-12 1985-03-12 Novo Industri As NEW PEPTIDES
EP0200383A3 (en) * 1985-04-15 1987-09-02 Eli Lilly And Company An improved method for administering insulin
DE3526995A1 (en) 1985-07-27 1987-02-05 Hoechst Ag FUSION PROTEINS, METHOD FOR THEIR PRODUCTION AND THEIR USE
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5496924A (en) 1985-11-27 1996-03-05 Hoechst Aktiengesellschaft Fusion protein comprising an interleukin-2 fragment ballast portion
DE3541856A1 (en) 1985-11-27 1987-06-04 Hoechst Ag EUKARYOTIC FUSION PROTEINS, THEIR PRODUCTION AND USE, AND MEANS FOR CARRYING OUT THE PROCESS
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
DE3544295A1 (en) * 1985-12-14 1987-06-19 Bayer Ag THERMOPLASTIC MOLDS WITH HIGH CROSS-CURRENT RESISTANCE
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
WO1988006599A1 (en) 1987-02-25 1988-09-07 Novo Industri A/S Novel insulin derivatives
US5034415A (en) * 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
DE3726655A1 (en) * 1987-08-11 1989-02-23 Hoechst Ag METHOD FOR ISOLATING BASIC PROTEINS FROM PROTEIN MIXTURES CONTAINING SUCH BASIC PROTEINS
DK257988D0 (en) 1988-05-11 1988-05-11 Novo Industri As NEW PEPTIDES
US6875589B1 (en) * 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE3827533A1 (en) * 1988-08-13 1990-02-15 Hoechst Ag PHARMACEUTICAL PREPARATION FOR TREATING THE DIABETES MELLITUS
DE3837825A1 (en) 1988-11-08 1990-05-10 Hoechst Ag NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
PT93057B (en) 1989-02-09 1995-12-29 Lilly Co Eli PROCESS FOR THE PREPARATION OF INSULIN ANALOGS
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5358857A (en) * 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
WO1991016929A1 (en) * 1990-05-10 1991-11-14 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
DK155690D0 (en) 1990-06-28 1990-06-28 Novo Nordisk As NEW PEPTIDES
DK10191D0 (en) * 1991-01-22 1991-01-22 Novo Nordisk As HIS UNKNOWN PEPTIDES
US6468959B1 (en) * 1991-12-05 2002-10-22 Alfatec-Pharm Gmbh Peroral dosage form for peptide containing medicaments, in particular insulin
US5614219A (en) * 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
DE59206324D1 (en) * 1991-12-05 1996-06-20 Alfatec Pharma Gmbh PHARMACEUTICAL APPLICABLE NANOSOL AND METHOD FOR THE PRODUCTION THEREOF
EP0600372B1 (en) 1992-12-02 1997-02-05 Hoechst Aktiengesellschaft Process for the preparation of proinsulin with correctly linked cystin bridges
MX9307991A (en) 1992-12-18 1994-08-31 Lilly Co Eli INSULIN ANALOGS, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL FORMULATIONS THAT INCLUDE THEM.
DE4400709B4 (en) * 1993-01-13 2005-06-23 Denso Corp., Kariya Screw fastening device
US5606203A (en) * 1993-01-20 1997-02-25 Kabushiki Kaisha Toshiba Semiconductor device having Al-Cu wiring lines where Cu concentration is related to line width
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
DE4405179A1 (en) 1994-02-18 1995-08-24 Hoechst Ag Method of obtaining insulin with correctly connected cystine bridges
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5559094A (en) 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
ES2151079T3 (en) 1994-09-09 2000-12-16 Takeda Chemical Industries Ltd PREPARATION OF SUSTAINED RELEASE CONTAINING A METALLIC SALT OF A PEPTIDE.
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
EP0831922A2 (en) 1995-06-08 1998-04-01 Therexsys Limited Improved pharmaceutical compositions for gene therapy
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
DE19545257A1 (en) * 1995-11-24 1997-06-19 Schering Ag Process for the production of morphologically uniform microcapsules and microcapsules produced by this process
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
DE19707245A1 (en) * 1997-02-25 1998-08-27 Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh Method of making an electric light bulb
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
CA2283705A1 (en) * 1997-03-20 1998-10-01 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
CO4750643A1 (en) 1997-06-13 1999-03-31 Lilly Co Eli STABLE FORMULATION OF INSULIN CONTAINING L-ARGININ AND PROTAMINE
DE19726167B4 (en) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, process for its preparation and pharmaceutical preparation containing it
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
WO1999024071A1 (en) 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
DE69924232D1 (en) * 1998-01-09 2005-04-21 Novo Nordisk As STABILIZED INSULIN PREPARATIONS
DK1121144T3 (en) 1998-10-16 2002-09-23 Novo Nordisk As Stable concentrated insulin preparations for pulmonary administration
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
CA2346884A1 (en) 1998-10-16 2000-04-27 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6635617B1 (en) * 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6489292B1 (en) * 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
DE69914934T2 (en) 1998-11-18 2005-01-05 Novo Nordisk A/S STABLE, AQUEOUS INSULIN PREPARATIONS WITHOUT PHENOL AND CRESOL
DE19908041A1 (en) * 1999-02-24 2000-08-31 Hoecker Hartwig Covalently bridged insulin dimers
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1187639A1 (en) * 1999-06-04 2002-03-20 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
KR100801588B1 (en) 1999-09-21 2008-02-05 스키에파마 캐나다 인코포레이티드 Surface Modified Particulate Composition of Bioactive Material
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
WO2001093837A2 (en) 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
KR100508695B1 (en) 2001-02-13 2005-08-17 한국과학기술연구원 Formulation for oral delivery of insulin and preparation method thereof
DE10114178A1 (en) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
CN1160122C (en) 2001-04-20 2004-08-04 清华大学 A kind of method for preparing oral insulin oil phase preparation
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
US20050123509A1 (en) 2001-10-19 2005-06-09 Lehrman S. R. Modulating charge density to produce improvements in the characteristics of spray-dried proteins
WO2003035051A2 (en) 2001-10-19 2003-05-01 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
US20060287221A1 (en) * 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia

Also Published As

Publication number Publication date
ZA200306637B (en) 2004-05-07
WO2002076495A1 (en) 2002-10-03
YU73503A (en) 2006-05-25
EP1381385A1 (en) 2004-01-21
RU2003131187A (en) 2005-03-10
HUP0303596A3 (en) 2005-11-28
CA2441260C (en) 2011-04-26
CN1273187C (en) 2006-09-06
HRP20030765A2 (en) 2005-06-30
ME00408B (en) 2011-10-10
NZ528335A (en) 2005-03-24
NO326780B1 (en) 2009-02-16
EP2289539B1 (en) 2012-09-19
US7696162B2 (en) 2010-04-13
ATE497777T1 (en) 2011-02-15
BRPI0208210B8 (en) 2021-05-25
PT1381385E (en) 2011-03-17
BRPI0208210B1 (en) 2018-05-02
HU228847B1 (en) 2013-06-28
MY129417A (en) 2007-03-30
CY1113318T1 (en) 2016-04-13
US20050187142A1 (en) 2005-08-25
TWI301761B (en) 2008-10-11
CA2441260A1 (en) 2002-10-03
DK2289539T3 (en) 2013-01-14
DE50214903D1 (en) 2011-03-24
PT2289539E (en) 2012-11-20
US20030004096A1 (en) 2003-01-02
AR033059A1 (en) 2003-12-03
IL158057A0 (en) 2004-03-28
AU2002302409B2 (en) 2007-01-04
DE10114178A1 (en) 2002-10-10
PL205465B1 (en) 2010-04-30
US20050187143A1 (en) 2005-08-25
JP2004523589A (en) 2004-08-05
ES2393180T3 (en) 2012-12-19
EP2289539A1 (en) 2011-03-02
AR096376A2 (en) 2015-12-23
HK1061521A1 (en) 2004-09-24
CY1111413T1 (en) 2015-08-05
SI1381385T1 (en) 2011-05-31
KR20100061868A (en) 2010-06-09
BR0208210A (en) 2004-03-09
US7205277B2 (en) 2007-04-17
JP4231292B2 (en) 2009-02-25
HUP0303596A2 (en) 2004-01-28
EP1381385B1 (en) 2011-02-09
HRP20030765B1 (en) 2011-10-31
KR20040011483A (en) 2004-02-05
RS51579B (en) 2011-08-31
PL362800A1 (en) 2004-11-02
US7452860B2 (en) 2008-11-18
KR100987311B1 (en) 2010-10-13
NO20034125L (en) 2003-11-11
US7205276B2 (en) 2007-04-17
DK1381385T3 (en) 2011-06-06
ES2360505T3 (en) 2011-06-06
US20070155653A1 (en) 2007-07-05
IL158057A (en) 2013-10-31
US6960561B2 (en) 2005-11-01
RU2311922C2 (en) 2007-12-10
NO20034125D0 (en) 2003-09-16
CN1498113A (en) 2004-05-19
US20090186807A1 (en) 2009-07-23
MXPA03007942A (en) 2004-04-02
PE20020968A1 (en) 2002-12-10

Similar Documents

Publication Publication Date Title
MEP60808A (en) Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability
MEP28708A (en) Acidic insulin preparations with improved stability
DE60104206D1 (en) SEMI-SOLID PREPARATION CONTAINING ISOTRETINOIN
EA200301275A1 (en) CAPSULES FOR INHALATION
NZ527157A (en) Compositions for delivering bisphosphonates
CY1110602T1 (en) PHARMACEUTICAL COMPOSITIONS IN THE FORM OF GEL OR SOLUTION BASED ON DIABROSTEOSTERONE, METHODS OF PREPARATION AND USES
WO2005115406A3 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
BR9810495A (en) Pharmaceutical composition
UA89315C2 (en) Butylbenzene phthalein intravenous emulsion
ATE311373T1 (en) OXADIAZOLE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE INGREDIENTS
ATE399847T1 (en) MULTIPLE EMULSION TYPE CLEANING AGENT
FI964285A0 (en) Pharmaceutical preparations based on derivatives belonging to the taxane class
DK1207756T3 (en) Use of spinosad or a formulation comprising spinosad
BRPI0309651A2 (en) method for preventing or reducing pesticide resistance of a substrate pest, pesticide composition, use thereof, and method for preparing a pesticide composition
RS50046B (en) PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDE AND NITAZOXANIDE
IT1320080B1 (en) COMPOSITION FOR PHARMACEUTICAL OR DIETARY USE.
CY1105847T1 (en) LINEAR BASIC COMPOUNDS EXHIBITING NK-2 ANTAGONIST ACTIVITY AND PREPARATION THEREOF
DE60232271D1 (en) AQUEOUS PHARMACEUTICAL FORMULATIONS OF WATER-SOLUBLE PRODRUGS OF PROPOFOL COMPOUNDS
AR028684A1 (en) NEW HERBICIDE COMPOSITIONS
BRPI0412453A (en) ascorbic acid or a physiologically acceptable salt thereof
DK1622447T3 (en) Aqueous liquid concentrate composition of pendimethalin
RS50074B (en) Paracetamol and drotaverine containing composition
BR9903567A (en) "pesticidal compositions"
BRPI0416154A (en) combination of t1, amiloride or triamterine antagonists, and a diuretic
DK1100463T3 (en) Injectable formulations containing ramoplanin